Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration
Comparative study reveals dosing challenges for ceftazidime and avibactam in critically ill children, highlighting need for drug monitoring.
Key Points
Higher dosing or continuous infusion of ceftazidime-avibactam is recommended for critically ill children under CRRT, with implications for treatment outcomes.
In this comparative study, pharmacokinetics of ceftazidime and avibactam were assessed through in vitro and in vivo methods, informing potential dosing strategies.
Therapeutic drug monitoring proved critical for optimizing ceftazidime-avibactam dosing during continuous venovenous hemodiafiltration.
This study emphasizes the challenges of addressing antimicrobial resistance in critically ill pediatric patients receiving renal replacement therapy.